SmithKline IBS Research Is One Of Nine Divestments Under FTC Order
Executive Summary
SmithKline Beecham is required to divest its rights to Alizyme's irritable bowel syndrome therapy renzapride under the FTC consent order allowing the GlaxoSmithKline merger despite Glaxo's recent withdrawal of Lotronex.
You may also be interested in...
GSK Cidra Manufacturing FDA-483 Reports Cite Ariflo, 12 Other Products
GlaxoSmithKline's pending chronic obstructive pulmonary disease therapy Ariflo (cilomilast) is among a dozen products manufactured in Cidra, Puerto Rico cited in recent FDA "Form 483" reports
GSK Cidra Manufacturing FDA-483 Reports Cite Ariflo, 12 Other Products
GlaxoSmithKline's pending chronic obstructive pulmonary disease therapy Ariflo (cilomilast) is among a dozen products manufactured in Cidra, Puerto Rico cited in recent FDA "Form 483" reports
FDA Lotronex Letter Cites Desire To Work With Glaxo To Maintain Therapy
FDA is willing to continue working with Glaxo Wellcome on a risk management program for Lotronex, the agency said in a Dec. 18 letter to consumers.